Cycle Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CYCLE, and when can generic versions of CYCLE drugs launch?
CYCLE has thirteen approved drugs.
There are four US patents protecting CYCLE drugs.
There are sixteen patent family members on CYCLE drugs in eighteen countries and twenty-four supplementary protection certificates in thirteen countries.
Summary for Cycle
| International Patents: | 16 |
| US Patents: | 4 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Cycle
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070354-001 | Jun 18, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-002 | Dec 9, 2022 | RX | Yes | Yes | 10,925,829 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cycle | CIMETIDINE | cimetidine | TABLET;ORAL | 074361-001 | Dec 23, 1994 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | 10,555,902 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cycle | CIMETIDINE HYDROCHLORIDE | cimetidine hydrochloride | SOLUTION;ORAL | 074541-001 | Aug 5, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cycle Drugs
Supplementary Protection Certificates for Cycle Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0627406 | SPC/GB11/026 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
| 1613288 | CR 2011 00023 | Denmark | ⤷ Sign Up | PRODUCT NAME: FINGOLIMOD, HERUNDER FINGOLIMOD SOM HYDROCHLORID; REG. NO/DATE: EU/1/11/677/001-004 20110317 |
| 1539166 | 2013/055 | Ireland | ⤷ Sign Up | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624 |
| 1613288 | C20110013 00043 | Estonia | ⤷ Sign Up | PRODUCT NAME: GILENYA - FINGOLIMOD; REG NO/DATE: FINAL 17.03.2011 |
| 0627406 | 2011020 | Ireland | ⤷ Sign Up | PRODUCT: GILENYA FINGOLIMOD AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF REGISTRATION NO/DATE: IRELAND EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011; FIRST REGISTRATION NO/DATE: EUROPEAN UNION EU/1/11/677/001, EU/1/11/677/002, EU/1/11/677/003, EU/1/11/677/004 / 17/03/2011 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
